Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Vivos Therapeutics (VVOS) FCF Margin (2020 - 2025)

Vivos Therapeutics (VVOS) has disclosed FCF Margin for 6 consecutive years, with 60.84% as the latest value for Q3 2025.

  • On a quarterly basis, FCF Margin rose 5260.0% to 60.84% in Q3 2025 year-over-year; TTM through Sep 2025 was 89.02%, a 86.0% decrease, with the full-year FY2024 number at 88.21%, down 162.0% from a year prior.
  • FCF Margin was 60.84% for Q3 2025 at Vivos Therapeutics, up from 111.65% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 50.47% in Q4 2021 to a low of 170.2% in Q1 2022.
  • A 5-year average of 99.7% and a median of 97.95% in 2023 define the central range for FCF Margin.
  • Peak YoY movement for FCF Margin: crashed -10688bps in 2021, then soared 7225bps in 2023.
  • Vivos Therapeutics' FCF Margin stood at 50.47% in 2021, then plummeted by -61bps to 81.34% in 2022, then dropped by -2bps to 83.13% in 2023, then dropped by -1bps to 83.96% in 2024, then grew by 28bps to 60.84% in 2025.
  • Per Business Quant, the three most recent readings for VVOS's FCF Margin are 60.84% (Q3 2025), 111.65% (Q2 2025), and 129.91% (Q1 2025).